RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

In a world first, researchers at the Kennedy Institute, Oxford have mapped the cellular dynamics following treatment with the ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

A year after the first samRNA vaccine approval, experts say similar vaccines in development are likely to face scientific and ...

A new study links the loss of a single copy of a noncoding gene to a rare neurodevelopmental disorder for the first time in human patients.

Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...

Unusual variations in the cellular protein factory can skew development, help cancer spread and more. But ribosome variety ...

Researchers describe the full molecular structure of the phage DEV. DEV infects and lyses Pseudomonas aeruginosa bacteria, an opportunistic pathogen in cystic fibrosis and other diseases. DEV is part ...

Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to ...

Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise ...

Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

The ALS Network, formerly ALS Golden West, has awarded a $125,000 grant through its global research program to AUTTX, LLC. to help develop novel therapeutics for people living with ALS. Led by ...